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of implantable cardioverter defibrillators.
Background. Sudden cardiac death is the single largest cause
of mortality in dialysis patients. There are no published data
on the use or survival impact of implantable cardioverter de-
fibrillators (ICDs) in dialysis patients. The objective of this ret-
rospective cohort study was to determine ICD use in dialysis
patients and impact on survival.
Methods. Dialysis patients hospitalized from 1996 to 2001
for ventricular fibrillation/cardiac arrest, having ICD implanta-
tion within 30 days of admission, discharged alive, and surviv-
ing at least 30 days from admission were identified from the
100% end-stage renal disease (ESRD) sample of the Medi-
care database. Long-term survival was estimated by life-table
method. Impact of independent predictors on survival was ex-
amined in a comorbidity-adjusted Cox model and a propensity
model.
Results. There were 460 patients (7.6%) with ICD and 5582
patients (92.4%) without ICD. Estimated 1-, 2-, 3-, 4-, and 5-year
survivals after day 30 of admission in the ICD group were 71%,
53%, 36%, 25%, and 22%, respectively; in the no-ICD group,
49%, 33%, 23%, 16%, and 12% (P < 0.0001). ICD implantation
was independently associated with a 42% reduction in death risk
[relative risk 0.58 (95% CI 0.50, 0.66)]. In the propensity model,
the relative risks of death for the lower, middle, and upper third
propensity groups were 0.45 (0.26, 0.81), 0.61 (0.45, 0.84), and
0.65 (0.55, 0.76), respectively. The C statistic for the propensity
model equaled 0.81.
Conclusion. In dialysis patients, ICD therapy is apparently
underused. ICD implantation in cardiac arrest survivors on dial-
ysis is associated with greater survival.
The risk of death in dialysis patients is extraordinarily
high. The rate of all-cause mortality for United States
dialysis patients in 1999 to 2001 was 235 deaths/1000
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patient-years [1]. Cardiac disease is the major cause of
death, accounting for 43% of all-cause mortality [1]. Dial-
ysis patients have poor long-term survival after acute my-
ocardial infarction (AMI) [2]; 20% of cardiac deaths are
attributed to AMI [1]. The single largest cause of death in
dialysis patients, however, is linked to arrhythmic mecha-
nisms, as 61% of all cardiac deaths are ascribed to cardiac
arrest/arrhythmia [1].
Dialysis patients are at high risk for sudden cardiac
death. As reported in the 2004 Annual Data Report of
the United States Renal Data System (USRDS), the rate
of cardiac arrest has decreased over the last decade. In
the prevalent United States dialysis patient population
the cardiac arrest rate (adjusted for age, gender, race,
and diabetic status) has declined from 75 events per 1000
patient years in 1994 to 62 events per 1000 patient years
in 2002 [3]. The hazard of cardiac arrest, however, is not
uniform over time for dialysis vintage, as the rate of car-
diac arrest progressively rises in relation to duration of
dialysis therapy [4]. Several factors contribute to the vul-
nerability of dialysis patients to sudden cardiac death:
obstructive coronary artery disease, left ventricular
hypertrophy, rapid electrolyte shifts in hemodialysis pa-
tients (and hyperkalemia), and abnormalities in myocar-
dial ultrastructure and function, including endothelial
dysfunction, interstitial fibrosis, decreased perfusion re-
serve, and diminished ischemia tolerance [5–8].
Dialysis patients suffer abysmal outcome after cardiac
arrest, having an 85% 1-year mortality [4]. In the gen-
eral population, implantable cardioverter defibrillators
(ICDs) have been shown to be superior to medical ther-
apy for improving the outcome of survivors of cardiac
arrest and life-threatening ventricular tachycardia [9]. Al-
though a nonsignificant survival advantage for ICDs was
reported in two other comparable trials [10, 11], a meta-
analysis of all three trials does suggest better survival with
ICDs, with a statistically significant (P = 0.0006) 28% re-
duction in death risk [12]. There are no published data on
ICD use and effect on survival in dialysis patients.
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METHODS
We performed a retrospective cohort study using the
100% end-stage renal disease (ESRD) sample of the
Medicare database (administrative data derived predom-
inantly from Medicare claims and identical to the source
of the United States Renal Data System database) (N =
1,408,250 patients). We studied period-prevalent dialy-
sis patients (1996 through 2001) who survived at least 90
days after dialysis initiation (N = 472,443), were hospital-
ized during the period January 1, 1996, to December 31,
2001, with an index event of cardiac arrest [International
Classification of Diseases, Ninth Revision, Clinical Mod-
ification (ICD-9-CM) code 427.5] or ventricular fibrilla-
tion/flutter (ICD-9-CM code 427.4) (N = 30,518), were
discharged alive from the hospital, and survived at least 30
days from the index admission (N = 6,173). ICD implan-
tation within 30 days of hospital admission was identified
from ICD-9-CM procedure code 37.94. Patients with a
prior ICD implant were excluded, yielding a final study
population of 6042 patients (identified from sequential
subsets as described above and further enumerated in
the Results section). Patients were followed from day 30
after admission to the earliest of death, renal transplan-
tation, loss to follow-up, or December 31, 2001.
Baseline characteristics of patients with and without
ICD were compared by v 2 test. Long-term survival was
estimated by life-table method, and survival of subgroups
compared by log-rank test. The impact of ICD implan-
tation on survival was estimated by a Cox proportional
hazards model, with adjustment for patient characteris-
tics, including age, gender, race, ESRD etiology, prior
ESRD duration, calendar year of hospitalization, con-
comitant AMI or coronary revascularization during hos-
pitalization, and comorbid medical conditions, the last
determined by using a previously developed comorbidity
profiling methodology [13].
To further analyze the impact of ICD implantation
on survival, and to account for the potential confound-
ing effects of differing characteristics of patients receiv-
ing ICDs and those not receiving ICDs on outcome, a
propensity model was used [14]. The propensity score for
a patient is the estimated probability of ICD implanta-
tion, given the characteristics of the patient. All variables
included in the Cox model were used in the propensity
model. Other variables added to the propensity analysis
were coronary angiography performed within 30 days of
the index admission, and two-way interactions of vari-
ables used in the Cox model. The propensity score was
incorporated into the Cox model through stratification by
propensity score tertiles. The C statistic was calculated in
the propensity model (with the study patients analyzed
by lowest, middle, and highest propensity tertiles for ICD
implantation) as a measure of strength of association of
ICD implantation with survival.
RESULTS
A total of 30,518 patients had an index event of cardiac
arrest or ventricular fibrillation/flutter, among whom 288
patients had a prior ICD implant, and these patients were
excluded (of these 288 patients with prior ICD implants,
131 survived at least 30 days and were discharged alive
from hospital). Of the remaining 30,230 patients, only
7853 patients were identified to be alive at 30 days af-
ter the index event. In this group of 7853 patients, 529
received ICD implants and 69 (13% of 529) died be-
fore discharge; a total of 1742 patients without ICD im-
plant (24% of 1742) died before discharge. There were
22,377 patients who were not eligible for inclusion (be-
cause they did not have at least 30-day survival after the
index event). Of these 22,377 patients, 37 received ICD
implants and 22 of these patients (59% of 37) died be-
fore discharge, while 22,340 patients did not receive ICD
implants and 21,258 (95% of 22,340) patients died before
discharge.
There were 6042 dialysis patients in the final study co-
hort. Only 460 patients (7.6%) received ICD therapy. The
mean ± SD age for the entire cohort was 63.1 ± 14.0 years
(ICD group, 63.1 ± 13.1 years; no-ICD group, 63.1 ± 14.2
years). The mean ± SD follow-up duration was 17.9 ±
15.5 months for the ICD group and 14.0 ± 14.9 months
for the no-ICD group. During the study period, the fol-
lowing occurred (numbers from ICD and no-ICD groups,
respectively): deaths 227 and 3858; renal transplants 8 and
101; and loss to follow-up 6 and 26.
Table 1 summarizes the patient characteristics. ICD
therapy was used relatively more frequently in patients
who were male, white, without diabetic ESRD, and with
AMI. Coronary angiography was performed in 1512 pa-
tients (25%). About one third (36.3%) of patients receiv-
ing ICDs did not have concurrent coronary angiography.
Diagnostic electrophysiologic studies were performed in
only 10.2% of the entire study cohort. Of the patients re-
ceiving EP studies, 416 did and 202 did not receive ICDs.
In the ICD group, 44 patients (9.6%) had no concurrent
claims for diagnostic electrophysiologic studies.
Figure 1 displays estimated survival. The 1-, 2-, 3-, 4-,
and 5-year survival in the ICD group was 71%, 53%, 36%,
25%, and 22%, respectively; in the no-ICD group, it was
49%, 33%, 23%, 16%, and 12% (P < 0.0001).
Table 2 provides the results of the Cox model. The
most powerful predictors of death were older age, dia-
betic ESRD, and the comorbid conditions of congestive
heart failure and peripheral vascular disease. ICD im-
plantation was independently associated with a 42% re-
duction in death risk [relative risk 0.58 (95% CI 0.50,
0.66)]. Surgical (but not percutaneous) coronary revas-
cularization during the same hospitalization was inde-
pendently associated with a 44% reduction in death
risk.
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Table 1. Baseline patient characteristics
All patients ICD No ICD
Characteristic (N = 6042) (N = 460) (N = 5582) P valuea
Age years (%) 0.007
<45 694 (11.5) 41 (8.9) 653 (11.7)
45 to 64 2118 (35.1) 167 (36.3) 1951 (35.0)
65 to 74 1896 (31.4) 170 (37.0) 1726 (30.9)
≥75 1334 (22.1) 82 (17.8) 1252 (22.4)
Gender number (%) <0.0001
Male 2833 (46.9) 262 (57.0) 2571 (46.1)
Female 3209 (53.1) 198 (43.0) 3011 (53.9)
Race number (%) 0.0961
White 3458 (57.2) 285 (62.0) 3173 (56.8)
Black 2218 (36.7) 152 (33.0) 2066 (37.0)
Other 366 (6.1) 23 (5.0) 343 (6.1)
End-stage renal disease etiology number (%) <0.0001
Diabetes 2854 (47.2) 164 (35.7) 2690 (48.2)
Hypertension 1605 (26.6) 127 (27.6) 1478 (26.5)
Other 1583 (26.2) 169 (36.7) 1414 (25.3)
Prior end-stage renal disease duration years (%)
<1 1268 (21.0) 95 (20.7) 1173 (21.0)
1 to <2 1243 (20.6) 89 (19.3) 1154 (20.7)
2 to <5 2159 (35.7) 154 (33.5) 2005 (35.9)
≥5 1372 (22.7) 122 (26.5) 1250 (22.4)
Comorbidity number (%)
Acute myocardial infarction 1361 (22.5) 132 (28.7) 1229 (22.0) 0.001
Atherosclerotic heart disease 3163 (52.4) 273 (59.3) 2890 (51.8) 0.0018
Congestive heart failure 3395 (56.2) 278 (60.4) 3117 (55.8) 0.0563
Cardiac (other) 3207 (53.1) 286 (62.2) 2921 (52.3) <0.0001
Cancer 591 (9.8) 52 (11.3) 539 (9.7) 0.2527
Chronic obstructive pulmonary disease 1396 (23.1) 95 (20.7) 1301 (23.3) 0.1941
Cerebrovascular accident/transient ischemic attack 1106 (18.3) 70 (15.2) 1036 (18.6) 0.0748
Gallbladder disease 422 (7.0) 30 (6.5) 392 (7.0) 0.6854
Gastrointestinal bleeding 1176 (19.5) 101 (22.0) 1075 (19.3) 0.16
Liver disease 185 (3.1) 11 (2.4) 174 (3.1) 0.3851
Peripheral vascular disease 2125 (35.2) 141 (30.7) 1984 (35.5) 0.0347
Concurrent events in hospital number (%)
Acute myocardial infarction 1094 (18.1) 103 (22.4) 991 (17.8) 0.013
Coronary artery bypass surgery 242 (4.0) 20 (4.3) 222 (4.0) 0.6967
Percutanous transluminal coronary angioplasty 273 (4.5) 34 (7.4) 239 (4.3) 0.002
Coronary artery stent 168 (2.8) 20 (4.3) 148 (2.7) 0.0334
Coronary angiogram 1512 (25.0) 293 (63.7) 1219 (21.8) <0.0001
Electrophysiologic study 618 (10.2) 416 (90.4) 202 (3.6) <0.0001
ICD is implantable cardioverter defibrillator.
aBy v 2 test.
The relation of ICD implantation and survival was as-
sessed in each tertile of propensity, (Table 3). In the low-
est propensity tertile for ICD implantation, there were
23 ICD patients, and the relative risk of death associated
with ICD was 0.45 (0.26, 0.81). In the middle third propen-
sity group, there were 78 ICD patients, and the relative
risk of death in the ICD group was 0.61 (0.45, 0.84). In
the upper third propensity tertile, there were 359 ICD
patients, and the relative risk of death in the ICD group
was 0.65 (0.55, 0.76). The C statistic for the propensity
model equaled 0.81. These data imply that the survival
advantage attributable to ICD implants was unlikely to
be explained by differences in baseline characteristics of
patients selected for ICD implantation compared to those
patients not receiving ICDs, as the survival advantage as-
sociated with ICD implantation was present in all three
tertiles of propensity.
DISCUSSION
This retrospective, observational study supports the
use of ICDs for the “secondary” prevention of death
in cardiac arrest survivors on dialysis. In this study the
apparent protective effect of ICDs was manifest surpris-
ingly early, as seen in the rapid divergence of the survival
curves. Although the contribution of selection bias to sur-
vival cannot be excluded (or apportioned), we believe
that these data imply that arrhythmic mechanisms play
an important role in the subsequent mortality of cardiac
arrest survivors on dialysis, and that ICDs may improve
survival in these patients.
Our study population of dialysis patients was char-
acterized by a high mortality rate, when viewed from
the perspective of ICD trials in non-ESRD patients. In
the Antiarrhythmics versus Implantable Defibrillators
(AVID) trial [9] comparing two treatment strategies for
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Fig. 1. Estimated unadjusted survival of dial-
ysis patients with and without an implantable
cardioverter-defibrillator (ICD). P < 0.0001
by log rank test for comparison of patients
with ICD to those without ICD. Dashed lines
indicate 95% CIs.
patients resuscitated from ventricular fibrillation, ventric-
ular tachycardia with syncope, or sustained ventricular
tachycardia (and ejection fraction of ≤40% and hemo-
dynamic compromise from the arrhythmia), the overall
mortality of patients was considerably lower than in our
present study. In AVID the reported 1-, 2-, and 3-year un-
adjusted life-table survivals were respectively 89%, 82%,
and 75% in the ICD arm and 82%, 75%, and 64% in
the patients receiving antiarrhythmic drugs. This con-
trasts with the unadjusted life-table survival in the present
study: the 1-, 2-, and 3-year survival were respectively
71%, 53%, and 36% for dialysis patients receiving ICDs
and 49%, 33%, and 23% for dialysis patients not receiv-
ing ICDs. Although the overall mortality in our dialysis
study population was much higher, the relative benefit
from ICDs was similar, with a 42% reduction in overall
death risk in our study and 38% in AVID.
Our data indicate that ICD therapy is apparently un-
derused in dialysis patients. To exclude moribund patients
(whom clinicians would be less likely to refer for ICD
implantation), we restricted our analysis to postcardiac
arrest 30-day survivors who had been discharged from
the hospital. Nevertheless, only 8% of the study cohort
received ICDs. Only 10% of the entire study cohort re-
ceived diagnostic electrophysiologic studies. Clearly, the
reason for not implanting an ICD was unrelated to a nega-
tive finding on a diagnostic electrophysiologic study. Our
study also raises an issue regarding selection of dialysis
patients for ICD therapy, as we observed an unbalanced
distribution of ICD implantation related to gender and
(and, to a lesser extent, race), with women and blacks less
likely to receive ICD therapy.
A recent publication by Voight et al [15] analyzed the
incidence of ICD therapy in survivors of cardiac arrest
in the United States from 1996 through 2001. There were
113,262 patients admitted for cardiac arrest and 49,517
patients survived to discharge. In this group of 49,517
patients, 30.7% received an ICD before discharge (rising
from 23.6% in 1996 to 46.3% in 2001). Race (black versus
white) [odds ratio 0.19 (95%CI 0.13, 0.29)] and renal fail-
ure (severity unspecified) [odds ratio 0.25 (95%CI 0.14,
0.46)] were found to be independent negative predictors
of ICD utilization in their study. Voight et al conclude
that the rates of ICD therapy after cardiac arrest remain
“very low.” Viewed from the perspective of Voight et al
that a 30.7% ICD utilization is “very low,” our finding
of a 7.6% ICD utilization reinforces our contention that
ICD therapy is underutilized in dialysis patients.
There are several plausible explanations for the appar-
ent underutilization of ICDs after cardiac arrest in dial-
ysis patients. It is plausible that concerns regarding po-
tential complications (e.g., infection and difficulties with
vascular access) might dissuade clinicians from ICD im-
plantation. Prior publications have reported that the like-
lihood of receiving therapies proven to reduce mortality
in clinical trials on treatment of AMI (including aspirin,
beta blockers, angiotensin converting enzyme inhibitors,
and reperfusion therapy) is inversely related to severity of
renal failure [16–20]. The underutilization of these ther-
apies in patients with chronic kidney disease may be a
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Table 2. Results of Cox proportional hazards model of all-cause mortality a
Hazards ratio (95% CI) P valuea
Implantable cardioverter defibrillator 0.58 (0.50, 0.66) <0.0001
Age years
<45 0.81 (0.72, 0.91) 0.0006
65 to 74 1.23 (1.14, 1.34) <0.0001
≥75 1.55 (1.42, 1.69) <0.0001
Gender
Male 1.06 (1.00, 1.13) 0.0563
Race
Black 0.91 (0.85, 0.97) 0.0052
Other 0.90 (0.78, 1.03) 0.1307
End-stage renal disease etiology
Diabetes 1.29 (1.19, 1.41) <0.0001
Hypertension 1.09 (0.99, 1.19) 0.0653
Prior end-stage renal disease duration years
1 to <2 1.01 (0.91, 1.11) 0.9097
2 to <5 1.04 (0.95, 1.13) 0.395
≥5 1.04 (0.94, 1.15) 0.4205
Comorbidity
Acute myocardial infarction 1.07 (0.99, 1.16) 0.0943
Atherosclerotic heart disease 1.05 (0.97, 1.13) 0.2202
Congestive heart failure 1.18 (1.10, 1.27) <0.0001
Cardiac (other) 1.04 (0.97, 1.12) 0.2217
Cancer 1.10 (1.00, 1.22) 0.0617
Chronic obstructive pulmonary disease 1.09 (1.01, 1.18) 0.0195
Cerebrovascular accident/transient ischemic attack 1.04 (0.96, 1.13) 0.3454
Gallbladder disease 0.98 (0.87, 1.11) 0.8027
Gastrointestinal bleeding 1.08 (1.00, 1.17) 0.0431
Liver disease 1.12 (0.94, 1.34) 0.1971
Peripheral vascular disease 1.26 (1.18, 1.35) <0.0001
Concurrent events in hospital
Acute myocardial infarction 1.13 (1.04, 1.23) 0.003
Coronary artery bypass surgery 0.56 (0.47, 0.67) <0.0001
Percutaneous transluminal coronary angioplasty 0.85 (0.66, 1.09) 0.2071
Coronary artery stent 0.91 (0.66, 1.25) 0.5666
Year of admission
1997 0.94 (0.85, 1.03) 0.1852
1998 0.91 (0.83, 1.00) 0.0579
1999 0.86 (0.78, 0.96) 0.0042
2000 0.83 (0.75, 0.93) 0.0008
2001 0.94 (0.82, 1.08) 0.3588
aThe reference group had the following characteristics: no ICD; age 45 to 64 years; female gender; white race; other end-stage renal disease etiology; prior end-stage
renal disease duration <1 year; no comorbid conditions; no concurrent events during hospital stay; prevalent dialysis patients in 1996.
reflection of both “therapeutic nihilism” and a paucity of
clinical trial data in this special group of high risk patients
[21]. Unfortunately, patients on dialysis are at high risk
for cardiac death and thus potentially have the most to
lose by not receiving life-saving therapies. This paradigm
applies equally to aspirin and defibrillators; if aspirin is
underprescribed, it should not be a surprise that ICDs
are underutilized.
The 2002 Guideline Update for Implantation of Car-
diac Pacemakers and Antiarrhythmia Devices from the
American College of Cardiology, American Heart As-
sociation, and North American Society for Pacing and
Electrophysiology is recommended as a definitive back-
ground source document for clinicians [22]. Three of the
“class I” (“conditions for which there is evidence and/or
general agreement that a given procedure or treatment
is beneficial, useful, and effective”) recommendations for
ICD therapy are pertinent to the present discussion: “car-
diac arrest due to ventricular fibrillation or ventricular
tachycardia not due to a transient or reversible cause,
spontaneous [ventricular tachycardia] in association with
structural heart disease, and spontaneous sustained [ven-
tricular tachycardia] patients without structural heart dis-
ease not amenable to other treatments. Two “class III
(“conditions for which there is evidence and/or gen-
eral agreement that a procedure/treatment is not use-
ful/effective and in some cases may be harmful) ICD
therapy recommendations are applicable to our discus-
sion: “ventricular tachycardia due to a transient or re-
versible disorder (e.g., AMI, electrolyte imbalance, drugs,
or trauma when correction of the disorder is considered
feasible and likely to substantially reduce the risk of re-
current arrhythmia” and “terminal illness with projected
life expectancy less than 6 months.”
In the present study we have focused on (presumably
nonmoribund) cardiac arrest survivors; arguably most
of these patients would have a class I indication for
ICD placement. It is also noteworthy that most dialysis
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patients probably do have some type of structural heart
disease, as left ventricular hypertrophy has been reported
in 75% of incident dialysis patients. One potential source
of confusion is the issue of “electrolyte imbalance” and
what is considered to be an easily treatable, potentially re-
versible condition whose correction is “likely to substan-
tially reduce the risk of recurrent arrhythmia” (even King
Solomon might have had difficulty applying this guide-
line to dialysis patients). Although the use of low potas-
sium dialyzate was a risk factor for cardiac arrest during
hemodialysis in one series, predialysis hyperkalemia was
not implicated [23]. Significantly, most cardiac arrests oc-
cur outside of dialysis centers (about one cardiac arrest
would be expected annually in a hemodialysis center with
100 chronic patients) [23, 24].
We believe that the key issue for clinicians caring for
these patients relates to the issue of clinical success by
therapeutic strategy. For whatever reason, 92% of our
study cohort did not receive ICDs. Based on their sub-
sequent outcome, it would be difficult to argue that this
group did well with a “conservative strategy.” In the con-
text of current ICD practice guidelines and the observa-
tional data presented in the present study, an increased
awareness by clinicians of the potential utility of ICDs in
dialysis patients would be desirable.
There are important limitations to this study. The data
were derived from Medicare claims; important clinical
data such as left ventricular ejection fraction, exercise ca-
pacity, serum potassium levels, and severity of coronary
artery disease were unavailable. Data regarding utiliza-
tion of pharmacologic agents (e.g., beta blockers) were
unavailable. In this retrospective study, the contribution
of selection bias for ICD use cannot be excluded.
Our study focused on the select 20% of dialysis patients
surviving 30 days after cardiac arrest and discharged alive
after hospitalization; these patients would be potential
candidates for “secondary” prevention of sudden cardiac
death. For most of the remaining 80% of the dialysis co-
hort hospitalized for cardiac arrest and not included in
our study, the clinical paradigm of “secondary” preven-
tion would not be applicable, either due to mortality or
postarrest clinical status. Our study ignored the larger
question of primary prevention of sudden cardiac death,
which is the single greatest contributor to all-cause mor-
tality in dialysis patients. Our data support studies on the
prevention of sudden cardiac death in dialysis patients,
including a prospective randomized trial of ICD therapy
for the primary prevention of sudden cardiac death in
dialysis patients.
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